RenovoRx Inc is a clinical-stage biopharmaceutical company. It is focused on developing therapies for the local treatment of solid tumors and conducting a Phase 3 registrational trial for lead product candidate RenovoGem. RenovoRx Inc is a clinical-stage biopharmaceutical company. It is focused on developing therapies for the local treatment of solid tumors and conducting a Phase 3 registrational trial for lead product candidate RenovoGem.
TIGeR-PaC is Evaluating the TAMP™ (Trans-Arterial Micro-Perfusion) Therapy Platform for the Treatment of Locally Advanced Pancreatic Cancer Dr. Meredith Pelster, Associate Director for GI...
LOS ALTOS, Calif., Dec. 10, 2024 (GLOBE NEWSWIRE) -- RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a life sciences company developing novel targeted oncology therapies and...
Over Ten Medical Institutions Nationwide have Initiated RenovoCath Purchase Process, Further Accelerating Commercialization Strategy RenovoRx Estimates Initial Target Market Size for RenovoCath...
The Northwell Health Cancer Institute is the Most Recent Clinical Site to Join the TIGeR-PaC Study, and RenovoRx Aims to Reach Full Patient Enrollment in the First Half of 2025 Phase III Clinical...
Near-Term Revenue Potential with Commercialization Plan for FDA-Cleared RenovoCath® Delivery System in Both Direct and Commercial Partner Channels Renowned Clinical Oncology Sites Participating...
期間 † | 前日比 | 前日比 % | 始値 | 高値 | 安値 | 平均出来高 | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.07 | -5.30303030303 | 1.32 | 1.39 | 1.1 | 84487 | 1.2101155 | CS |
4 | -0.05 | -3.84615384615 | 1.3 | 1.58 | 1.1 | 120501 | 1.30650316 | CS |
12 | 0.17 | 15.7407407407 | 1.08 | 1.58 | 0.7736 | 62849 | 1.22613621 | CS |
26 | -0.09 | -6.71641791045 | 1.34 | 1.58 | 0.7736 | 48796 | 1.18555752 | CS |
52 | 0.5404 | 76.1555806088 | 0.7096 | 2.35 | 0.678 | 58333 | 1.36092437 | CS |
156 | -4.18 | -76.9797421731 | 5.43 | 5.745 | 0.5306 | 95513 | 2.40123474 | CS |
260 | -7 | -84.8484848485 | 8.25 | 16.74 | 0.5306 | 384755 | 7.56953324 | CS |
顧客サポート: +44 (0) 203 8794 460 | support@advfn.com
ADVFNのサービスをご利用いただくには、利用規約